Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for DIVISLAB
Revenue projections for DIVISLAB

DIVISLAB's revenue is projected to decrease from last year, a development that could lead investors to adopt a more cautious approach. A revenue decline can negatively affect profitability, signaling challenges for the company and making it less attractive for those seeking solid financial performance.

Financial Ratios:

currentRatio 0.000000
forwardPE 49.568996
debtToEquity 0.027000
earningsGrowth 0.265000
revenueGrowth 0.138000
grossMargins 0.603400
operatingMargins 0.256020
trailingEps 86.940000
forwardEps 56.300000

DIVISLAB's positive earnings and revenue growth indicate that the company is well-positioned for business expansion. This growth suggests a strong financial trajectory, with DIVISLAB expected to continue increasing its profits and revenue in the coming periods.
With positive gross and operating margins, Divi's Laboratories Limited's profitability is evident. These metrics suggest the company is efficiently managing its expenses while maintaining strong revenue, highlighting a solid financial foundation.
DIVISLAB's forward EPS is less than its trailing EPS, signaling that the company's profitability is expected to shrink. This points to a potential downturn in earnings compared to last year.

Price projections:

Price projections for DIVISLAB
Price projections for DIVISLAB

Over time, price projections for Divi's Laboratories Limited have gradually risen, signaling growing optimism about the company's future. This upward revision reflects increasing confidence in Divi's Laboratories Limited's ability to achieve strong financial results.

Insider Transactions:

Insider Transactions for DIVISLAB
Insider Transactions for DIVISLAB


DIVISLAB saw 20 transactions in which shares were sold with market price at 5805.552514648438.2 separate purchases of DIVISLAB stock were made, while market price was at 5854.875 per share.Investors are purchasing DIVISLAB more frequently than selling it near the current price levels, which might point to a bullish sentiment. This pattern could be interpreted as a favorable outlook for the stock's future.

Recommendation changes over time:

Recommendations trend for DIVISLAB
Recommendations trend for DIVISLAB


The analysts' sell bias for DIVISLAB suggests caution for investors, but it's essential to make decisions based on a wide array of market indicators. This approach ensures a comprehensive view of DIVISLAB's position, helping to navigate any potential risks more effectively.